Showing results (41-50 of 123) with videos related to
Sort By:
Pageof 13
Drug Discovery Today|March 21, 2016
Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumorsAnnelieke E C A B Willemsen, Floor J E Lubberman, Jolien Tol, et al.Cancers|June 10, 2023
Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?Eline L Giraud, Loek A W de Jong, Erik van den Hombergh, et al.Therapeutic Drug Monitoring|July 27, 2019
Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human PlasmaErik van den Hombergh, Nikki de Rouw, Michel van den Heuvel, et al.Cancer Chemotherapy and Pharmacology|January 19, 2026
Mapping drug-drug interactions in pharmacokinetic boosting of olaparibJoanneke K Overbeek, Sarmad M S Naoom, Laura Nijboer, et al.Clinical Pharmacokinetics|June 15, 2016
A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer PatientsNielka P van Erp, Carla M van Herpen, Djoeke de Wit, et al.British Journal of Clinical Pharmacology|September 30, 2023
Results of the first international quality control programme for oral targeted oncolyticsEline L Giraud, Lindsey M H Te Brake, Erik C A van den Hombergh, et al.Clinical Pharmacokinetics|February 5, 2025
Population Pharmacokinetics of Cobicistat and its Effect on the Pharmacokinetics of the Anticancer Drug OlaparibJoanneke K Overbeek, Nielka P van Erp, David M Burger, et al.European Journal of Cancer (Oxford, England : 1990)|March 28, 2025
Safety of accelerated infusion of nivolumab and pembrolizumabLoes van Rijssen, Iris E C Nagtegaal, Floortje K Ploos van Amstel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinibNielka P van Erp, Hans Gelderblom, Mats O Karlsson, et al.Journal of Immunology Research|June 9, 2020
Successful Regulatory T Cell-Based Therapy Relies on Inhibition of T Cell Effector Function and Enrichment of FOXP3+ Cells in a Humanized Mouse Model of Skin InflammationS Landman, V L de Oliveira, M Peppelman, et al.Pageof 13